MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Inclusion Criteria

• •1. Written informed consent must be signed before implementing any enrollment-related procedures;
• •2. Age ≥18 years old;
• •3. Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)；
• •4. There is no special restriction on the source of genetic test report.
• •5. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion.
• •6. Have not received any previous systemic antitumor therapy for advanced diseases.
• •7. No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system.
• •8. ECOG score: 0-1;
• •9. Expected survival time \> 3 months.